Beijing IP Court issues first ruling on protecting AI model parameters; Chinese pharma companies are using “NewCo” strategy ...

A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

I think we’ve come a long way in understanding the importance of this biology. We know it affects men and women, children and ...

Jiangsu Hengrui Pharmaceuticals Co. Ltd. is the latest mainland China pharmaceutical company to seek a capital raise on the Hong Kong stock exchange, winning clearance April 28 from the China ...

Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, ...